Thyrocare Technologies Ltd

Thyrocare Tech. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Thyrocare Technologies Ltd

₹ 452 -2.15%
18 May - close price
thyrocare.com BSE: 539871 NSE: THYROCARE
About

Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.

Key Points

Business Segments
1) Diagnostic Testing Services (92% in FY25 vs 94% in FY22): [1] [2] The company is one of the leading Pan-India diagnostic chains, offering a range of tests focused on early disease detection and health management. It provides 929 tests and 288 profiles, including 43 wellness packages under the “Aarogyam” brand. It processes 3 Bn investigations annually and can process 10 Bn annually. [3] [4]

Website BSE NSE
  • Market Cap ₹ 7,197 Cr.
  • Current Price ₹ 452
  • High / Low ₹ 538 / 291
  • Stock P/E 43.0
  • Book Value ₹ 36.8
  • Dividend Yield 1.55 %
  • ROCE 36.7 %
  • ROE 29.6 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 12.3 times its book value
  • Promoters have pledged 100% of their holding.
  • Promoter holding has decreased over last 3 years: -10.2%
  • Working capital days have increased from 35.2 days to 85.5 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
136 135 148 135 154 157 177 166 187 193 217 196 224
111 100 110 103 121 115 129 124 130 135 145 138 149
Operating Profit 25 35 38 32 34 42 48 42 57 58 71 58 75
OPM % 18% 26% 25% 23% 22% 27% 27% 25% 30% 30% 33% 30% 34%
4 1 3 3 3 4 3 4 5 5 3 -1 5
Interest 1 1 1 1 1 1 1 1 1 1 1 -0 2
Depreciation 11 10 11 13 13 11 13 17 14 11 12 22 14
Profit before tax 17 25 28 20 23 34 37 28 47 50 63 35 64
Tax % 28% 31% 28% 26% 25% 29% 28% 32% 54% 24% 24% 21% 24%
12 17 20 15 17 24 26 19 22 38 48 28 49
EPS in Rs 0.79 1.09 1.28 0.97 1.12 1.52 1.68 1.20 1.36 2.45 3.02 1.82 2.96
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
183 241 304 356 403 434 495 589 527 572 687 829
110 147 189 212 249 261 323 353 403 432 498 567
Operating Profit 73 94 115 145 154 174 171 236 123 140 190 262
OPM % 40% 39% 38% 41% 38% 40% 35% 40% 23% 24% 28% 32%
8 7 -15 21 11 1 12 29 9 9 15 12
Interest 0 1 0 0 1 2 1 3 5 6 4 3
Depreciation 13 18 18 20 26 32 30 34 39 47 55 59
Profit before tax 68 82 82 145 138 140 152 228 89 96 145 213
Tax % 35% 37% 48% 36% 38% 37% 26% 23% 27% 28% 38% 24%
44 52 43 93 85 88 113 176 64 69 91 163
EPS in Rs 2.98 3.21 2.66 5.79 5.38 5.58 7.13 11.10 4.06 4.45 5.76 10.24
Dividend Payout % 171% 104% 125% 58% 124% 30% 117% 45% 148% 135% 122% 0%
Compounded Sales Growth
10 Years: 13%
5 Years: 11%
3 Years: 16%
TTM: 21%
Compounded Profit Growth
10 Years: 13%
5 Years: 9%
3 Years: 38%
TTM: 93%
Stock Price CAGR
10 Years: 8%
5 Years: 6%
3 Years: 43%
1 Year: 40%
Return on Equity
10 Years: 21%
5 Years: 21%
3 Years: 20%
Last Year: 30%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 51 54 54 54 53 53 53 53 53 53 53 159
Reserves 226 312 354 390 382 314 374 474 481 474 494 426
0 0 0 0 2 12 8 21 23 42 25 51
53 44 30 36 37 90 106 60 74 75 121 111
Total Liabilities 329 410 438 479 475 469 541 607 632 644 693 747
196 259 259 299 294 269 253 285 294 306 297 317
CWIP 6 1 17 0 1 5 8 3 2 3 14 3
Investments 86 93 104 120 95 90 126 146 144 162 162 177
42 56 58 60 84 105 154 173 192 173 220 250
Total Assets 329 410 438 479 475 469 541 607 632 644 693 747

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
34 68 90 107 100 168 115 113 129 168 191 213
-18 -18 -42 -43 -12 1 -49 -24 -39 -91 -53 -23
-23 -45 -49 -64 -94 -165 -62 -89 -86 -85 -130 -170
Net Cash Flow -6 5 -0 -0 -5 4 4 0 4 -8 8 21
Free Cash Flow 25 53 53 63 61 158 93 99 88 107 146 198
CFO/OP 79% 106% 113% 108% 104% 122% 92% 72% 128% 141% 123% 104%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 10 11 8 10 11 14 33 58 59 28 39 33
Inventory Days 48 56 65 66 60 64 52 53 62 104 89 81
Days Payable 5 10 6 25 25 68 56 36 54 88 146 109
Cash Conversion Cycle 53 57 67 50 46 10 29 75 67 44 -18 4
Working Capital Days 28 2 19 10 28 -8 19 41 31 7 13 86
ROCE % 24% 28% 33% 30% 35% 36% 42% 17% 18% 25% 37%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Tests Conducted
Million

Log in to view insights

Please log in to see hidden values.

Login
Number of Samples Processed (Pathology)
Million
Number of Active Franchisees
Count
Number of Labs (Pathology)
Count
Number of PET-CT Scans (Radiology)
Count
Average Lab Turnaround Time (Post-receipt)
Hours

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

17 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
71.14% 71.14% 71.11% 71.11% 71.11% 71.11% 71.06% 71.06% 71.06% 71.06% 60.93% 60.92%
3.44% 3.46% 3.35% 2.90% 2.49% 1.93% 2.77% 2.41% 3.23% 4.85% 4.96% 5.37%
13.46% 13.33% 13.89% 14.88% 14.89% 14.79% 14.68% 14.97% 14.54% 13.47% 20.52% 21.00%
11.95% 12.08% 11.64% 11.11% 11.49% 12.15% 11.49% 11.57% 11.18% 10.61% 13.61% 12.71%
No. of Shareholders 76,29272,00068,84464,82361,63659,37756,66657,40354,56654,14277,61973,377

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls